AVEO Pharma (AVEO) -12.5% premarket even as its Q4 net loss narrowed from the year-ago quarter, primarily due to a milestone from Astellas recognized upon the acceptance of a new drug filing. But AVEO also announced disappointing results for its tivozanib drug from a Phase 3 TIVO-1 study in patients with advanced renal cell carcinoma.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs